|
2025 Journal Article Disinfectant and antibiotic resistance in Mycobacterium abscessus water isolatesPatterson-Fahy, Kirby, Carter, Robyn, Taylor, Steven L., Guo, Jianhua and Thomson, Rachel M. (2025). Disinfectant and antibiotic resistance in Mycobacterium abscessus water isolates. Microbiology Spectrum, 13 (7) e0337424, 1-12. doi: 10.1128/spectrum.03374-24 |
|
2025 Journal Article P101 Prevalence of nausea and vomiting and anti-emetic use in the tinding the optimal regimen for Mycobacterium abscessus treatment (Format) trialWainwright, C., Hicks, D., Rice, M., Jong, T., Joshi, S., Wang, X., Burke, A., Thomson, R., Grimwood, K., Bell, S. and Clark, J. (2025). P101 Prevalence of nausea and vomiting and anti-emetic use in the tinding the optimal regimen for Mycobacterium abscessus treatment (Format) trial. Journal of Cystic Fibrosis, 24, S98. doi: 10.1016/j.jcf.2025.03.119 |
|
2025 Journal Article P100 Adverse events related to study drugs in finding the optimal regimen for Mycobacterium abscessus treatment (FORMaT) trialWainwright, C., Hicks, D., Rice, M., Jong, T., Gailer, N., Joshi, S., Wang, X., Burke, A., Thomson, R., Grimwood, K., Bell, S. and Clark, J. (2025). P100 Adverse events related to study drugs in finding the optimal regimen for Mycobacterium abscessus treatment (FORMaT) trial. Journal of Cystic Fibrosis, 24, S97-S98. doi: 10.1016/j.jcf.2025.03.118 |
|
2025 Journal Article World Bronchiectasis 2025—Inclusive Lungs, Diverse SolutionsThomson, Rachel Mary and Morgan, Lucy Catriona (2025). World Bronchiectasis 2025—Inclusive Lungs, Diverse Solutions. Respirology, 30 (7), 552-554. doi: 10.1111/resp.70063 |
|
2025 Conference Publication Efficacy of Ethambutol Rechallenge in Patients With Prior Ethambutol-induced Optic Toxicity for the Treatment of Mycobacterium Avium Complex Pulmonary DiseaseYeo, B., Goh, F. and Thomson, R. (2025). Efficacy of Ethambutol Rechallenge in Patients With Prior Ethambutol-induced Optic Toxicity for the Treatment of Mycobacterium Avium Complex Pulmonary Disease. ATS International Conference, San Francisco, CA United States, 16-21 May 2025. New York, NY United States: American Thoracic Society. |
|
2025 Conference Publication Prevalence of Nausea and Vomiting and Anti-emetic Use in the Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (FORMaT) TrialThomson, R., Hicks, D., Rice, M., Jong, T., Joshi, S., Wang, X., Burke, A.J., Grimwood, K., Bell, S., Clark, J. and Wainwright, C.E. (2025). Prevalence of Nausea and Vomiting and Anti-emetic Use in the Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (FORMaT) Trial. ATS International Conference, San Francisco, CA United States, 16-21 May 2025. New York, NY United States: American Thoracic Society. doi: 10.1164/ajrccm.2025.211.abstracts.a7277 |
|
2025 Conference Publication Adverse Events Related to Study Drugs in Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (Format) TrialThomson, R., Hicks, D., Rice, M., Jong, T., Gailer, N., Joshi, S., Wang, X., Burke, A. J., Grimwood, K., Bell, S., Clark, J. and Wainwright, C. E. (2025). Adverse Events Related to Study Drugs in Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (Format) Trial. 52nd Critical Care Congress of the Society of Critical Care Medicine (SCCM), San Francisco, CA United States, 21-24 January 2023. New York, NY United States: American Thoracic Society. |
|
2025 Conference Publication Adverse Events Related to Study Drugs in Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (Format) TrialThomson, R., Hicks, D., Rice, M., Jong, T., Gailer, N., Joshi, S., Wang, X., Burke, A.J., Grimwood, K., Bell, S., Clark, J. and Wainwright, C.E. (2025). Adverse Events Related to Study Drugs in Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (Format) Trial. ATS International Conference, San Francisco, CA United States, 16-21 May 2025. New York, NY United States: American Thoracic Society. doi: 10.1164/ajrccm.2025.211.abstracts.a7278 |
|
2025 Conference Publication Gut Microbiome Signatures Discriminate Nontuberculous Mycobacterial Pulmonary Disease Patients Requiring Treatment From Those With Stable DiseaseThompson, R., Lim, Y., Goh, F., Blumenthal, A., Morrison, M. and Thomson, R. (2025). Gut Microbiome Signatures Discriminate Nontuberculous Mycobacterial Pulmonary Disease Patients Requiring Treatment From Those With Stable Disease. ATS International Conference, San Francisco, CA United States, 16-21 May 2025. New York, NY United States: American Thoracic Society. |
|
2025 Conference Publication Real-world Experience With Inhaled Liposomal Amikacin Suspension for Treatment of Nontuberculous Mycobacterial Pulmonary DiseaseTwining, M., Kang, S., Riddles, T., Evans, I., Burke, A. J. and Thomson, R. (2025). Real-world Experience With Inhaled Liposomal Amikacin Suspension for Treatment of Nontuberculous Mycobacterial Pulmonary Disease. ATS International Conference, San Francisco, CA United States, 16-21 May 2025. New York, NY United States: American Thoracic Society. |
|
2025 Conference Publication Real-world Experience With Inhaled Liposomal Amikacin Suspension for Treatment of Nontuberculous Mycobacterial Pulmonary DiseaseTwining, M., Kang, S., Riddles, T., Evans, I., Burke, A.J. and Thomson, R. (2025). Real-world Experience With Inhaled Liposomal Amikacin Suspension for Treatment of Nontuberculous Mycobacterial Pulmonary Disease. ATS International Conference, San Francisco, CA United States, 16-21 May 2025. New York, NY United States: American Thoracic Society. doi: 10.1164/ajrccm.2025.211.abstracts.a5444 |
|
2025 Conference Publication Prevalence of Nausea and Vomiting and Anti-emetic Use in the Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (FORMaT) TrialThomson, R., Hicks, D., Rice, M., Jong, T., Joshi, S., Wang, X., Burke, A. J., Grimwood, K., Bell, S., Clark, J. and Wainwright, C. E. (2025). Prevalence of Nausea and Vomiting and Anti-emetic Use in the Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (FORMaT) Trial. 52nd Critical Care Congress of the Society of Critical Care Medicine (SCCM), San Francisco, CA United States, 21-24 January 2023. New York, NY United States: American Thoracic Society. |
|
2025 Journal Article A pilot study to assess the effect of intermittent inhaled nitric oxide as treatment of nontuberculous mycobacteria lung infectionThomson, Rachel M., Burke, Andrew J., Morgan, Lucy C. and Colin, Andrew A. (2025). A pilot study to assess the effect of intermittent inhaled nitric oxide as treatment of nontuberculous mycobacteria lung infection. Annals of the American Thoracic Society, 22 (7), 1092-1097. doi: 10.1513/annalsats.202407-745rl |
|
2025 Journal Article Infection by clonally related Mycobacterium abscessus isolates: the role of drinking waterThomson, Rachel M., Wheeler, Nicole, Stockwell, Rebecca E., Bryant, Josephine, Taylor, Steven L, Leong, Lex E. X., Le, Trieu, Rogers, Geraint B, Carter, Robyn, Sherrard, Laura J, Powell, Harry, Simpson, Graham, Patterson-Fahy, Kirby, Wainwright, Claire E., Floto, R. Andres, Parkhill, Julian and Bell, Scott C. (2025). Infection by clonally related Mycobacterium abscessus isolates: the role of drinking water. American Journal of Respiratory and Critical Care Medicine, 211 (5), 842-853. doi: 10.1164/rccm.202409-1824oc |
|
2025 Conference Publication The aetiology and epidemiology of nontuberculous mycobacteria (NTM) in Australians with CFDuplancic, C., Alene, K., Thomson, R., Wainwright, C., Rogers, G., Clements, A., Floto, A. and Bell, S. (2025). The aetiology and epidemiology of nontuberculous mycobacteria (NTM) in Australians with CF. TSANZSRS Annual Scientific meeting 2025, Adelaide, SA Australia, 21-25 March 2025. Richmond, VIC Australia: John Wiley & Sons. |
|
2025 Conference Publication Adverse events related to study drugs in finding the optimal regimen for mycobacterium abscessus treatment (format) trialHicks, D., Rice, M., Jong, T., Gailer, N., Joshi, S., Wang, X., Thomson, R., Burke, A., Grimwood, K., Bell, S., Clark, J. and Wainwright, C. (2025). Adverse events related to study drugs in finding the optimal regimen for mycobacterium abscessus treatment (format) trial. TSANZSRS Annual Scientific meeting 2025, Adelaide, SA Australia, 21-25 March 2025. Richmond, VIC Australia: John Wiley & Sons. |
|
2025 Journal Article Pediatric physiotherapy management of airway clearance therapy and exercise: data from the Australian Bronchiectasis RegistryWebb, Elizabeth M., Holland, Anne E., Chang, Anne B., Middleton, Peter G., Thomson, Rachel, Wong, Conroy, Jayaram, Lata, Holmes‐Liew, Chien‐Li, Morgan, Lucy and Lee, Annemarie L. (2025). Pediatric physiotherapy management of airway clearance therapy and exercise: data from the Australian Bronchiectasis Registry. Pediatric Pulmonology, 60 (1) e27370, 1-9. doi: 10.1002/ppul.27370 |
|
2024 Journal Article Current physiotherapy practice for adults with bronchiectasis: data from the Australian Bronchiectasis RegistryWebb, Elizabeth M., Holland, Anne E., Chang, Anne B., Burr, Lucy, Holmes-Liew, Chien-Li, King, Paul T., Middleton, Peter G., Morgan, Lucy, Thomson, Rachel M., Wong, Conroy and Lee, Annemarie L. (2024). Current physiotherapy practice for adults with bronchiectasis: data from the Australian Bronchiectasis Registry. Respiratory Medicine, 233 107777, 1-8. doi: 10.1016/j.rmed.2024.107777 |
|
2024 Journal Article Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 monthsHaworth, Charles S., Shteinberg, Michal, Winthrop, Kevin, Barker, Alan, Blasi, Francesco, Dimakou, Katerina, Morgan, Lucy C., O'Donnell, Anne E., Ringshausen, Felix C., Sibila, Oriol, Thomson, Rachel M., Carroll, Kevin J., Pontenani, Federica, Castellani, Paola, Chalmers, James and PROMIS Trial Investigators, (2024). Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months. Lancet Respiratory Medicine, 12 (10), 787-798. doi: 10.1016/-2600(24)00225-X |
|
2024 Conference Publication Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: Results of two randomized double-blind placebo-controlled phase 3 trials assessing safety and efficacy over 12 monthsHaworth, Charles, Shteinberg, Michal, Winthrop, Kevin, Barker, Alan, Blasi, Francesco, Dimakou, Katerina, Morgan, Lucy, O'Donnell, Anne, Ringhausen, Felix, Sibila, Oriol, Thomson, Rachel, Carroll, Kevin, Pontenani, Federica, Castellani, Paola and Chalmers, James (2024). Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: Results of two randomized double-blind placebo-controlled phase 3 trials assessing safety and efficacy over 12 months. 2024 ERS Congress, Vienna, Austria, 7–11 September 2024. Sheffield, United Kingdom: European Respiratory Society. doi: 10.1183/13993003.congress-2024.rct5390 |
